Taurus Vascular

Executive Summary

Taurus Vascular is a Houston-based medical device company focused on improving long-term outcomes for patients with aortic aneurysms. The company is developing a minimally invasive technology designed to address endoleaks, a common and serious complication following endovascular aneurysm repair (EVAR). Endoleaks often require reintervention and can lead to aneurysm rupture, representing a significant unmet need in vascular surgery. Taurus Vascular's proprietary platform aims to prevent endoleaks by reinforcing the aneurysm sac, thereby reducing reintervention rates and improving patient survival. Founded in 2010, the company has spent years refining its technology and is now approaching clinical validation. The market for aortic aneurysm repair is substantial, with over 100,000 EVAR procedures performed annually in the US alone. Despite advances, endoleaks occur in 20-30% of patients, creating a need for effective adjunctive therapies. Taurus Vascular's solution, if proven, could become a standard of care in EVAR procedures, offering a unique value proposition to hospitals and payers by reducing costly reinterventions. While the company is privately held and has not disclosed funding or clinical milestones, its long development history suggests a mature preclinical or early clinical stage. Near-term catalysts include progression to first-in-human studies and potential regulatory designations.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial60% success
• Q2 2026FDA Breakthrough Device Designation70% success
• Q3 2026Series C Funding Round or Strategic Partnership55% success